Related references
Note: Only part of the references are listed.Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody
Christian Augsberger et al.
BLOOD (2021)
Current State of Immunotherapy for Treatment of Glioblastoma
Tresa McGranahan et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
EGFRvIII: An Oncogene with Ambiguous Role
Adrianna Rutkowska et al.
JOURNAL OF ONCOLOGY (2019)
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
Patrick C. Gedeon et al.
CLINICAL CANCER RESEARCH (2018)
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2018)
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Zhenyi An et al.
ONCOGENE (2018)
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
Pakawat Chongsathidkiet et al.
NATURE MEDICINE (2018)
Advances in immunotherapy for the treatment of glioblastoma
Amanda Tivnan et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Targeting Malignant Brain Tumors with Antibodies
Rok Razpotnik et al.
FRONTIERS IN IMMUNOLOGY (2017)
Highly Specific and Effective Targeting of EG FRvIII-Positive Tumors with TandAb Antibodies
Kristina Ellwanger et al.
FRONTIERS IN ONCOLOGY (2017)
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2016)
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Tilman Schlothauer et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
OPINION Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma
Frank B. Furnari et al.
NATURE REVIEWS CANCER (2015)
Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies
Patrick Roth et al.
NEURO-ONCOLOGY (2014)
EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180
H. Feng et al.
ONCOGENE (2014)
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Anoop P. Patel et al.
SCIENCE (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Targeting T cells to tumor cells using bispecific antibodies
Stanley R. Frankel et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2013)
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
Bryan D. Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
Christian Klein et al.
MABS (2012)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13R alpha 2, gp100 and TRP-2 for immunotherapy
Stephan Saikali et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
AB Heimberger et al.
CLINICAL CANCER RESEARCH (2005)